|
|
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseWithdrawn |
First Approval Ctry. / Loc.United States |
First Approval Date29 Sep 1989 |
|
|
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseWithdrawn |
First Approval Ctry. / Loc.United States |
First Approval Date26 Aug 1988 |
Randomized, Double-Masked, Vehicle-controlled Phase III Trial on the Safety/Efficacy of FML® 0.1% in the Treatment of the Inflammatory Exacerbation Provoked by Exposure to an Adverse Controlled Environment in Patients With Dry Eye Disease
Hypothesis: Fluorometholone (FML) 0.1% eyedrops topically applied 4 times a day for 22 days is more efficient than artificial tears (Liquifilm) in dry eye disease (DED) and ameliorates the worsening of the disease after exposure to an adverse controlled environment.
Start Date01 Feb 2014 |
Sponsor / Collaborator- |
100 Clinical Results associated with DHPS x GR
100 Translational Medicine associated with DHPS x GR
0 Patents (Medical) associated with DHPS x GR